Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the Degradation of Dystrophin and Dystrophin-Associated Proteins in mdx Mice

Duchenne Muscular Dystrophy (DMD) is an incurable inherited disease ofchildhood, characterized by progressive muscle degeneration and weakness. Our previousfindings supported the idea that dystrophin and associated proteins, absent or greatlyreduced in DMD, are degraded in dystrophin-deficient muscl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell cycle (Georgetown, Tex.) Jg. 6; H. 10; S. 1242 - 1248
Hauptverfasser:	Bonuccelli, Gloria, Sotgia, Federica, Capozza, Franco, Gazzerro, Elisabetta, Minetti, Carlo, Lisanti, Michael P.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Taylor & Francis 15.05.2007
Schlagworte:	Animals Binding Biology Bioscience Boronic Acids - pharmacology Bortezomib Calcium Cancer Cell Cycle Dipeptides - pharmacology Dystrophin - metabolism Dystrophin-Associated Proteins - metabolism Landes Male Mice Mice, Inbred mdx Microscopy, Fluorescence Muscle, Skeletal - metabolism Muscular Dystrophy, Duchenne - drug therapy Muscular Dystrophy, Duchenne - metabolism NF-kappa B - metabolism Organogenesis Protease Inhibitors - pharmacology Proteins Pyrazines - pharmacology
ISSN:	1538-4101, 1551-4005, 1551-4005
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!